Immatics

Immatics turned up the heat at the 20th Annual BioHouston Chili Cookoff! This year’s event held a special meaning as attendees gathered in loving memory of Ann Tanabe. Her presence was deeply missed and it was moving to see the Houston biotech community come together to honor her legacy. At the event, the Immatics team introduced SUPRAME Market, a supermarket-themed tent inspired by SUPRAME, our ongoing Phase 3 clinical trial evaluating our lead cell therapy product candidate, ACTengine® IMA203 TCR-T, in patients with advanced melanoma. Not only did we offer delicious chili but we were the go-to spot for fresh fruits and pressed juice. What else happened? 🌶️ Our Director of OQA Sameer Sharma endured the spice and came in 2nd place in the Jalapeño Eating Contest! 💃🏼 Our Immatics team members, led by Arely Wahl, continued to bring the heat with a choreographed performance that brought the crowd to life. 🛒 From beet hummus to carrot cake, our SUPRAME Market tent was a one-stop shop for foodies of all kinds. There were so many creative tents and delicious chilis! We are so honored to be a part of such a special day celebrating community and connection with other biotech industry professionals. #BioHouston #BioHoustonChiliCookOff #HoustonLifeSciences #BiotechHouston

Comprehensive clinical data on ACTengine® IMA203 TCR T-cell therapy were recently published in Nature Medicine. The manuscript includes encouraging results from 40 heavily pretreated patients with solid tumors, including melanoma, mostly treated during the Phase 1a dose escalation part of the trial. Read the publication here: https://lnkd.in/dzHJZJXK What’s next for ACTengine® IMA203 TCR T? 👉IMA203 is currently being evaluated in, SUPRAME, a randomized-controlled Phase 3 trial in advanced melanoma patients. 👉In addition to cutaneous melanoma, Immatics intends to expand the IMA203 TCR-T opportunity to treat uveal melanoma patients and will continue to evaluate IMA203 in this patient population through the ongoing Phase 1b trial. Springer Nature #CellTherapy #Healthcare #Biotech #Science #Cancer #Melanoma #Tcells

In case you missed it: Last week we announced our year-end financial results and a business update. Click here for the full announcement: https://lnkd.in/d353kfZe #FinancialResults #PressRelease #QuarterlyReport #CompanyNews #Oncology

Last week, our Vice President Late-Stage Development, Delfi Krishna, took the stage at the #IO360Summit for her presentation, “Delivering the Power of T cells to Patients with Solid Cancers.” Here are two key takeaways from the event: 🔹The IO360° Summit brought together industry professionals, investors and physicians, fostering insightful discussions on topics such as immunotherapy innovations and lessons learned from landmark trials. 🔹 The Women’s Luncheon was an inspiring gathering, featuring conversations on strategies for navigating complex conversations and expanding mentorship and sponsorship opportunities. Immatics has attended this conference in the past, and it was once again a valuable opportunity to connect and exchange insights that drive innovation in cancer immunotherapies. Immuno-Oncology 360° Community News #ImmunoOncology #CancerResearch #Innovation #IO360

Today we announced our full year financial results and provided a business update. Click here to access the full press release: https://lnkd.in/d353kfZe #FinancialResults #PressRelease #QuarterlyReport #CompanyNews #Healthcare #Biotech

“Perseverance is essential—success in the biotech field does not happen overnight, and although it’s a long game, the impact on people’s lives makes it all worth it!” – Steffen Walter Last week, our COO, Steffen Walter, participated in the Immunology Program 2025 Retreat in Galveston, Texas, where he spoke on the Industry Panel alongside other biotech leaders, addressing an audience of Ph.D. students and MD Anderson faculty members. The panel covered topics ranging from clinical research and publishing data to the unique opportunities and challenges of working in biotech start-ups. Steffen highlighted Houston’s strong biotech sector, emphasizing its distinguished medical institutions, affordability and talent pool. As the discussion continued, Steffen shared insights on his journey in the industry—from co-founding Immatics with trusted colleagues to working relentlessly to develop and advance novel TCR-based immunotherapies for patients with cancer. 💭 To the students in the room, Steffen left a compelling question: Who will be the next CEO to launch a biotech company in Houston? The industry is evolving rapidly and, in a few years, today’s students could be the next generation of biotech leaders. Thank you to UT MD Anderson Cancer Center UTHealth Houston Graduate School of Biomedical Sciences for hosting such an engaging retreat and to the students for their insightful questions. We’re excited to see what the future of biotech holds for these bright minds! #Biotech #Immunology #CancerResearch #Innovation #HoustonBiotech

Collaboration is at the heart of everything we do. From the lab to manufacturing or even on the pickleball court! Our GMP, MST and GPS teams came together for their quarterly team building event. From volunteering to friendly competitions, these teams gather to reinforce teamwork and strengthen connections that fuel our mission of making an impact on the lives of patients with cancer. We love seeing the energy and teamwork that drives innovation - on and off the court! #TeamWork #Together #TeamBuilding #Chemistry #Manufacturing #Control

The Immatics team, including Paula Franson, Liane Preußner, Karine Pozo, PhD and Dmitry Pankov, MD, are onsite at the Society of Gynecologic Oncology’s Annual Meeting on Women’s Cancer in Seattle, Washington! 💡 Did you know that endometrial cancer (uterine cancer) is the most common gynecologic cancer, and 1 in 71 women will develop ovarian cancer in their lifetime*? With statistics like these, our mission at Immatics is clear: to make a meaningful impact on the lives of patients with solid tumors by advancing our novel cell and bispecific immunotherapies. Currently, our second-generation TCR T-cell therapy, IMA203CD8 targeting PRAME, is being evaluated in a Phase 1 clinical trial with the goal of treating a broader patient population, including those with ovarian and uterine cancers. 👉 Interested in learning more? Reach out to the team: medinfo@immatics.com *According to the Foundation for Women’s Cancer #SGOMtg #MultiplyYourImpact #SGO2025 #GynecologicOncology #OncologyResearch #Healthcare #Biotech

Meet us in Mainz! Our Chief Medical Officer, Cedrik M. Britten, will be speaking at the Mostly (T) Cell Therapy Symposium at the University Medical Center Mainz. See the details below to ensure you don’t miss this insightful presentation: 🔸Mar 12, 6:00 pm CET – Presentation: PRAME-specific TCR (TCER® IMA402) Therapy in Patients with Solid Tumors Learn more about Cedrik’s talk and other conference details here: https://lnkd.in/d6Dm-cJ7 *Please note the information is in German. #CellTherapy #SolidTumors #Cancer #Immunotherapy #Oncology

Last week, the Greater Houston Partnership hosted the Bayou City Bio Pulse event at Immatics—a fantastic gathering of industry professionals, leaders and innovators! In collaboration with BioHouston and the Cancer Prevention and Research Institute of Texas, this event provided an opportunity to network and gain insights into the future of Houston’s life science sector and growing role as a leading biotech hub. Our VP of Human Resources & US Site Head, Tamara Louw, and our COO, Steffen Walter, welcomed the attendees who enjoyed presentations on topics such as advancements in manufacturing from CRB and funding opportunities from CPRIT. It was a pleasure to connect with so many dedicated professionals and we look forward to the continued growth of Houston’s biotech sector! #BayouCityBioPulse #BioHouston #HoustonBiotech #LifeSciences #CancerResearch